{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:03:01Z","timestamp":1771063381802,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>The management of melasma is an ongoing challenge. Platelet-rich plasma (PRP) therapy has been reported to be beneficial, but there is paucity of studies on PRP therapy in melasma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To compare the efficacy of PRP therapy and hydroquinone versus hydroquinone alone in melasma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>Thirty patients were randomized to receive PRP microinjections on one side and normal saline on the other in a total of 3 sittings. Patients were concurrently advised 4% hydroquinone (HQ) cream application on both sides of the face. Efficacy was evaluated with hemi-modified Melasma Area Severity Index (MASI) scoring and a 4-scale patient satisfaction grading.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Majority of the subjects (53.3%) in PRP + HQ group and 76.7% in HQ group had 25% to 50% improvement in their MASI scores. However, 40% in the PRP + HQ group and only 3.3% in the HQ group had 51% to 75% improvement. The difference in the percentage improvement was statistically significant. There was a greater percentage of subjects reporting a good response among the HQ + PRP group (53.3%) as compared with the HQ group (27%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Microinjections of PRP combined with topical HQ has better efficacy than topical HQ alone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003403","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T12:08:41Z","timestamp":1644494921000},"page":"429-434","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Role of Platelet-Rich Plasma Therapy as an Adjuvant in Treatment of Melasma"],"prefix":"10.1097","volume":"48","author":[{"given":"Chingshubam","family":"Bikash","sequence":"first","affiliation":[{"name":"Department of Dermatology, Maulana Azad Medical College, New Delhi, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lady Hardinge Medical College, New Delhi, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Relhan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Maulana Azad Medical College, New Delhi, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarika","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Maulana Azad Medical College, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.det.2007.05.004","article-title":"Pigmentary disorders in India","volume":"25","author":"Pasricha","year":"2007","journal-title":"Dermatol Clin"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/2349-5847.147044","article-title":"Recent advances in melasma","author":"Chatterjee","year":"2014","journal-title":"Pigment Int"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5021\/ad.2014.26.3.401","article-title":"Regression of melasma with platelet-rich plasma treatment","volume":"26","author":"Cay\u0131rl\u0131","year":"2014","journal-title":"Ann Dermatol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/DSS.0000000000001559","article-title":"Platelet-rich plasma therapy in the treatment of recalcitrant melasma","volume":"45","author":"Garg","year":"2019","journal-title":"Dermatol Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5021\/ad.2011.23.4.424","article-title":"Can platelet-rich plasma Be used for skin rejuvenation? Evaluation of effects of platelet-rich plasma on human dermal fibroblast","volume":"23","author":"Kim","year":"2011","journal-title":"Ann Dermatol"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/0378-6323.125467","article-title":"Platelet rich plasma in dermatology: boon or a bane?","volume":"80","author":"Arshdeep","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-2077.118403","article-title":"A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma","volume":"6","author":"Budamakuntla","year":"2013","journal-title":"J Cutan Aesthet Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"8350317","DOI":"10.1155\/2018\/8350317","article-title":"Evaluation of therapeutic efficacy and safety of tranexamic acid local infiltration in combination with topical 4% hydroquinone cream compared to topical 4% hydroquinone cream alone in patients with melasma: a split-face study","volume":"2018","author":"Tehranchinia","year":"2018","journal-title":"Dermatol Res Pract"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molcel.2008.11.002","article-title":"Inhibition of PAX3 by TGF-\u03b2 modulates melanocyte viability","volume":"32","author":"Yang","year":"2008","journal-title":"Mol Cell"},{"key":"R12-20250731","first-page":"1482","article-title":"Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation","volume":"36","author":"Kim","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1111\/dsu.12348","article-title":"Epidermal growth factor and epidermal growth factor signaling attenuate laser-induced melanogenesis","volume":"39","author":"Yun","year":"2013","journal-title":"Dermatol Surg"},{"key":"R14-20250731","first-page":"87","article-title":"Treatment of periorbital hyperpigmentation using platelet-rich plasma injections","volume":"3","author":"Al-Shami","year":"2014","journal-title":"Am J Dermatol Venereol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4161\/derm.21923","article-title":"Hyaluronic acid: a key molecule in skin aging","volume":"4","author":"Papakonstantinou","year":"2012","journal-title":"Dermatoendocrinol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/09546634.2018.1524821","article-title":"Platelet rich plasma is a useful therapeutic option in melasma","volume":"30","author":"Hofny","year":"2019","journal-title":"J Dermatol Treat"},{"key":"R17-20250731","first-page":"1","article-title":"Platelet\u2010rich plasma treatment for melasma: a pilot study","volume":"19","author":"Sirithanabadeekul","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546630050517333","article-title":"A double blind,comparative, placebo controlled study of the efficacy and tolerability of 4% hydroquinone in melasma","volume":"11","author":"Ennes","year":"2000","journal-title":"J Dermatol Treat"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:08:05Z","timestamp":1753999685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003403","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}